84
Participants
Start Date
November 30, 2013
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
JNJ-38877618: Part 1a
Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
JNJ-38877618: Part 1b
Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
JNJ-38877618: Part 1c (optional)
Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
JNJ-38877618: Part 2
Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
JNJ-38877618: Part 3
Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
JNJ-38877618: Part 4 (optional)
Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
Placebo: Parts 1a, 2, 3, and 4 (optional)
Administered orally matched to study drug
Nottingham
Janssen Cilag N.V./S.A.
INDUSTRY